{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:12:16Z","timestamp":1794017536843,"version":"4.8.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI148684"],"award-info":[{"award-number":["UM1AI148684"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI148684"],"award-info":[{"award-number":["UM1AI148684"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI148684"],"award-info":[{"award-number":["UM1AI148684"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI148684"],"award-info":[{"award-number":["UM1AI148684"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI148684"],"award-info":[{"award-number":["UM1AI148684"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01261-3","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:13:53Z","timestamp":1763979233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine"],"prefix":"10.1038","volume":"10","author":[{"given":"Lisa A.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Deye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrick","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pecor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenn","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Posavad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Lundeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjodh","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindan","family":"Kalyanasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afzal A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1261_CR1","unstructured":"Schistosomiasis (Bilharzia), <https:\/\/www.who.int\/health-topics\/schistosomiasis#tab=tab_1> (2024)."},{"key":"1261_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-031-60121-7_3","volume":"1454","author":"PT LoVerde","year":"2024","unstructured":"LoVerde, P. T. Schistosomiasis. Adv. Exp. Med Biol. 1454, 75\u2013105 (2024).","journal-title":"Adv. Exp. Med Biol."},{"key":"1261_CR3","doi-asserted-by":"publisher","unstructured":"Yamey, G. et al. Vaccine value profile for schistosomiasis. Vaccine. 126020. https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.068 (2024)","DOI":"10.1016\/j.vaccine.2024.05.068"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.vaccine.2015.12.032","volume":"34","author":"AX Mo","year":"2016","unstructured":"Mo, A. X. & Colley, D. G. Workshop report: Schistosomiasis vaccine clinical development and product characteristics. Vaccine 34, 995\u20131001 (2016).","journal-title":"Vaccine"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2307\/3282583","volume":"75","author":"Y Zhou","year":"1989","unstructured":"Zhou, Y. & Podesta, R. B. Effects of serotonin (5HT) and complement C3 on the synthesis of the surface membrane precursors of adult Schistosoma mansoni. J. Parasitol. 75, 333\u2013343 (1989).","journal-title":"J. Parasitol."},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/infdis\/jir545","volume":"204","author":"G Ahmad","year":"2011","unstructured":"Ahmad, G. et al. Preclinical Prophylactic Efficacy Testing of Sm-p80-Based Vaccine in a Nonhuman Primate Model of Schistosoma mansoni Infection and Immunoglobulin G and E Responses to Sm-p80 in Human Serum Samples From an Area Where Schistosomiasis Is Endemic. J. Infect. Dis. 204, 1437\u20131449 (2011).","journal-title":"J. Infect. Dis."},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1016\/j.vaccine.2009.02.096","volume":"27","author":"G Ahmad","year":"2009","unstructured":"Ahmad, G. et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 27, 2830\u20132837 (2009).","journal-title":"Vaccine"},{"key":"1261_CR8","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00436-009-1646-z","volume":"105","author":"G Ahmad","year":"2009","unstructured":"Ahmad, G. et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol. Res 105, 1767\u20131777 (2009).","journal-title":"Parasitol. Res"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.vaccine.2013.12.057","volume":"32","author":"S Karmakar","year":"2014","unstructured":"Karmakar, S. et al. Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons. Vaccine 32, 1296\u20131303 (2014).","journal-title":"Vaccine"},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/infdis\/jiu031","volume":"209","author":"S Karmakar","year":"2014","unstructured":"Karmakar, S. et al. Use of an Sm-p80-Based Therapeutic Vaccine to Kill Established Adult Schistosome Parasites in Chronically Infected Baboons. J. Infect. Dis. 209, 1929\u20131940 (2014).","journal-title":"J. Infect. Dis."},{"key":"1261_CR11","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1007\/s00436-017-5634-4","volume":"116","author":"AJ Molehin","year":"2017","unstructured":"Molehin, A. J. et al. Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80\/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium. Parasitol. Res. 116, 3175\u20133188 (2017).","journal-title":"Parasitol. Res"},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00436-014-3879-8","volume":"113","author":"W Zhang","year":"2014","unstructured":"Zhang, W. et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol. Res. 113, 2239\u20132250 (2014).","journal-title":"Parasitol. Res"},{"key":"1261_CR13","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3389\/fimmu.2020.01246","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer Protection in vivo and in vitro From Schistosoma mansoni and Identification of Putative Correlative Markers of Protection. Front Immunol. 11, 1246 (2020).","journal-title":"Front Immunol."},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nyas.13942","volume":"1425","author":"W Zhang","year":"2018","unstructured":"Zhang, W. et al. Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy. Ann. N. Y. Acad. Sci. 1425, 38\u201351 (2018).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1016\/j.vaccine.2019.08.075","volume":"37","author":"WA Keitel","year":"2019","unstructured":"Keitel, W. A. et al. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine 37, 6500\u20136509 (2019).","journal-title":"Vaccine"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/imm.12711","volume":"150","author":"JE Igetei","year":"2017","unstructured":"Igetei, J. E., El-Faham, M., Liddell, S. & Doenhoff, M. J. Antigenic cross-reactivity between Schistosoma mansoni and peanut: a role for cross-reactive carbohydrate determinants (CCDs) and implications for the hygiene hypothesis. Immunology 150, 506\u2013517 (2017).","journal-title":"Immunology"},{"key":"1261_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01044-2","volume":"10","author":"DWB Kifle","year":"2025","unstructured":"Kifle, D. W. B. et al. A Functional Enzymatic Assay as Potential Readout for a Clinical Trial of a Schistosomiasis Vaccine. NPJ Vaccines 10, 48 (2025).","journal-title":"NPJ Vaccines"},{"key":"1261_CR18","doi-asserted-by":"publisher","first-page":"e0011236","DOI":"10.1371\/journal.pntd.0011236","volume":"17","author":"DJ Diemert","year":"2023","unstructured":"Diemert, D. J. et al. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl. Trop. Dis. 17, e0011236 (2023).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1261_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113160","volume":"499","author":"SE Larsen","year":"2021","unstructured":"Larsen, S. E. et al. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. J. Immunol. Methods 499, 113160 (2021).","journal-title":"J. Immunol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01261-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:17:21Z","timestamp":1764181041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01261-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01261-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.A.D. is currently an employee of AstraZeneca. D.C. is a shareholder in PAI Life Sciences Inc. which holds a license to the SchisoShield\u00ae product.All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}